A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626 ·Status: UNKNOWN ·Phase: PHASE2

Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

NCT04600947 ·Status: UNKNOWN ·Phase: PHASE2

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

NCT05615974 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

The Study of ICP-248 in Patients With Mature B-cell Malignancies

NCT05728658 ·Status: RECRUITING ·Phase: PHASE1

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

NCT02597153 ·Status: TERMINATED ·Phase: PHASE2

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

NCT05400876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT05221645 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

NCT04082936 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors

NCT02929615 ·Status: UNKNOWN ·Phase: PHASE4

A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma

NCT04693676 ·Status: UNKNOWN ·Phase: PHASE1

A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma

NCT05495100 ·Status: UNKNOWN ·Phase: PHASE2

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT04844866 ·Status: RECRUITING ·Phase: PHASE2

Lenalidomide Based Immunotherapy in the Treatment of DLBCL

NCT03715296 ·Status: UNKNOWN

Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

NCT05429918 ·Status: UNKNOWN

A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

NCT03235544 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Glofitamab in Chinese Patients With R/R DLBCL

NCT06481826 ·Status: RECRUITING

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

NCT04129710 ·Status: RECRUITING ·Phase: PHASE2

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

NCT05590221 ·Status: RECRUITING ·Phase: PHASE2

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT05564052 ·Status: COMPLETED ·Phase: PHASE2

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267 ·Status: COMPLETED ·Phase: PHASE1

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT01466868 ·Status: TERMINATED ·Phase: PHASE2

A Study of Mitoxantrone Hydrochloride Liposome Infusion

NCT02856685 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2